-
Watch HOPE Summit 2026 Videos
HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer.
For...
IN THE SPOTLIGHT
-
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community... -
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from... -
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to... -
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who... -
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their... -
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
Initial Treatment Options for HER2+ NSCLC Expand with New Zongertinib Approval
On February 26, 2026, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) as an initial treatment option for newly diagnosed... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both...
Non-Small Cell Lung Cancer (NSCLC): Molecular Markers, Immune Therapy and Targeted Therapy
Non-Small Cell Lung Cancer (NSCLC): Molecular Markers, Immune Therapy and Targeted Therapy
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026
FDA Approves FoundationOne CDx as Companion Diagnostic for TEPMETKO in METex14 NSCLC
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initi
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initi
Prognostic significance of ypN status after neoadjuvant chemoimmunotherapy in resectable NSCLC: a systematic review and meta-analysis
Prognostic significance of ypN status after neoadjuvant chemoimmunotherapy in resectable NSCLC: a systematic review and meta-analysis
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting